Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001
The development of tissue-engineered skin (Apligraf; Organogenesis Inc, Canton, Mass), which has been approved for venous leg ulcers and diabetic neuropathic foot ulcers, has offered a new option for patients with chronic wounds.1 How tissue-engineered skin heals chronic wounds is under investigation, but it appears to work primarily as a stimulus to healing, likely through the production of various cytokines.
Long RE, Falabella AF, Valencia I, Eaglstein WH, Kirsner RS. Treatment of Refractory, Atypical Lower Extremity Ulcers With Tissue-Engineered Skin (Apligraf). Arch Dermatol. 2001;137(12):1660-1661. doi: